C-HIODScholar Rock
latent growth factors, monoclonal antibodies, TGFβ biology
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-HIOD
C-HIODC-HIODlatent growth factors, monoclonal antibodies, TGFβ biology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Scholar Rock latent growth factors, monoclonal antibodies, TGFβ biology
Scholar Rock is a biopharmaceutical company focused on discovering, developing, and delivering therapies for serious diseases. Its therapeutic approach selectively targets growth factors in their latent form before activation, with programs across neuromuscular disease, immuno-oncology, fibrotic disease, and hematology. The company applies its platform to protein growth factors in the TGFβ superfamily and has advanced monoclonal antibodies into clinical development.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Scholar Rock — Near-term readout · Bottom quartile. Derived deterministically from 8 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic